Conference Description
The MHC-Restricted Antigen Processing and Presentation GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field. The conference is five days long and held in a remote location to increase the sense of camaraderie and create scientific communities, with lasting collaborations and friendships. In addition to premier talks, the conference has designated time for poster sessions from individuals of all career stages, and afternoon free time and communal meals allow for informal networking opportunities with leaders in the field.
This Gordon Research Conference will explore the basic mechanisms of MHC-restricted antigen processing and presentation at the intersection of immunity, autoimmunity, tolerance and cancer immunotherapy. Recent advances in mass spectrometry have led to more accurate identification and quantification of the MHC-immunopeptidome. Therefore, this meeting will focus on how the defined MHC-immunopeptidomes have been utilized to make important advances in the understanding and manipulation of T cell responses. The initial sessions will focus on the complex biochemical pathways that mediate MHC classical and non-classical ligand generation and loading with an emphasis on the diversity of the immunopeptidome, antigen cross-presentation, endosomal pathways of presentation, and proteasome dependent and independent pathways that collectively generate the MHC peptidome. Subsequent sessions will explore how the presented MHC-immunopeptidome shapes and promotes T cell tolerance while promoting T cell responses to pathogens but yet tolerating the microbiome. Importantly, the conference will also explore how the selected MHC-immunopeptidome drives immunological responses in autoimmunity and cancer and how it can be harnessed for immunotherapy.
The conference will consist of nine sessions, on the topics listed below. The conference chair is currently developing their preliminary program, which will include the names of the invited speakers and discussion leaders for each of these sessions. The preliminary program will be available by May 14, 2025. Please check back for updates.
